[Effects of Tangshenling Mixture and benazepril on rats with diabetic nephropathy and its mechanism].
OBJECTIVE
To investigate the effects of Tangshenling Mixture (TSLM) and benazepril on rats with diabetic nephropathy (DN) and its mechanism.


METHODS
Diabetic nephropathy was induced in rats by intraperitoneal injection of streptozotocin. Fifty-eight rats with DN were randomly divided into four groups: untreated group, TSLM-treated group, TSLM plus benazepril-treated group and benazepril-treated group. Another seven normal rats were included in normal control group. Then, rats in each group were accordingly given normal saline, TSLM, TSLM plus benazepril and benazepril orally for six weeks respectively. Blood and urine biochemical indexes, plasma atrial natriuretic factor (ANF), pathomorphology of renal tissue, transforming growth factor beta1 (TGF-beta1) and glucose transporter 1 (GLUT1) mRNAs in renal tissue were observed.


RESULTS
Both TSLM and benazepril could decrease urinary albumin excretion rates, creatinine clearance and ratio of kidney weight to body weight of the rats with DN as well as reduce the pathological damages of the renal tissues. TSLM could reduce the level of plasma ANF and the expression of GLUT1 mRNA, but had no significant effect on the expression of TGF-beta1 mRNA. Benazepril could reduce the expression of TGF-beta1 mRNA, but had no significant effect on plasma ANF and the expression of GLUT1 mRNA.


CONCLUSIONS
TSLM can reduce the pathological damages of renal tissues in rats with early-stage DN, and its mechanism may relate to decreasing the level of plasma ANF and the expression of GLUT1 mRNA which is different from that of benazepril. It seems that TSLM has synergetic effect with benazepril.
He
Xue-Lin
XL
Nephrology Center, First Hospital, Medical School, Zhejiang University, Hangzhou, Zhejiang Province 310003, China. hexuelin88@hotmail.com
Li
Jian-Ping
JP
Chen
Yi-Ping
YP
Zhang
Zhi-Gang
ZG
Lin
Wei-Qin
WQ
Chen
Jiang-Hua
JH
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D001552:Benzazepines / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D051272:Glucose Transporter Type 1 / Q000096:biosynthesis* / Q000235:genetics; D007668:Kidney / Q000378:metabolism; D008297:Male; D008517:Phytotherapy; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D016212:Transforming Growth Factor beta / Q000096:biosynthesis* / Q000235:genetics; D053773:Transforming Growth Factor beta1
D000806:Angiotensin-Converting Enzyme Inhibitors; D001552:Benzazepines; D004365:Drugs, Chinese Herbal; D051272:Glucose Transporter Type 1; C508962:Tgfb1 protein, rat; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; C044946:benazepril